Access to this content is restricted
Learning objectives:
- Understand the principles of detection/quantification of ctDNA fraction and CTC count as prognostic or response biomarkers in prostate cancer
- Understand the potentials of liquid biopsy profiling for advanced prostate cancer stratification and precision oncology
- Understand potentials from a serial liquid biopsy to reveal prostate cancer evolution and mechanisms of drug resistance
This webinar aims to review and discuss data for liquid biopsy-based assessments as endpoints of antitumour activity in clinical trials, understand the potential and limitations of liquid biopsy-based tumour genomic profiling for patient stratification and detection of predictive biomarkers of response to therapy, and to discuss how tumour heterogeneity and evolution assessed via liquid biopsy assays may improve colorectal cancer treatment strategies.